PMC5223009_01
CT scan of the chest (a) before nivolumab treatment, (b) after 3 cycles of nivolumab treatment, and (c) osimertinib day 14.
CRIONM2016-1075641.001.jpg
PMC5223009_01_CRIONM2016-1075641.001.jpg
fig1
At this time, disease progression was observed with an increase in the primary tumor size (Figure 1(a) arrow) and multiple brain metastases, but disease progression was still considered indolent. However, rapid lung cancer progression was observed with an increase the size of the primary lesion located in the right upper lobe (Figure 1(b) arrow), multiple novel nodules on both lungs (Figure 1(b)), and multiple novel brain metastases. After 14 days of osimertinib initiation, a whole-body CT revealed drastic shrinkage of the primary lung tumor (Figure 1(c) arrow) and multiple metastatic lung lesions (Figure 1(c)).